Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: One-year results of a randomized trial

Ophthalmology

Volumn 121, Issue 2, 2014, Pages 558-565

  Bae, So Hyun ^a   Heo, Jangwon ^b,c   Kim, Cinoo ^d   Kim, Tae Wan ^b   Shin, Joo Young ^b,c   Lee, Joo Yong ^e   Song, Su Jeong ^f   Park, Tae Kwann ^g   Moon, Sang Woong ^h   Chung, Hum ^b,c  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Gongdeok Seoul Eye Clinic Renaissnace Tower Bldg   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Soonchunhyang University   (South Korea)

^h Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CENTRAL RETINAL THICKNESS; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; PATIENT SAFETY; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL FLUID; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; COLORING AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; LASER THERAPY, LOW-LEVEL; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETINA; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84895068821     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.09.024     Document Type: Article

References (30)

1. B.C. Polak, G.S. Baarsma, and B. Snyers Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment Br J Ophthalmol 79 1995 922 925
2. J.D. Gass Pathogenesis of disciform detachment of the neuroepithelium Am J Ophthalmol 63 suppl 1967 1 139
3. K. Hayashi, Y. Hasegawa, and T. Tokoro Indocyanine green angiography of central serous chorioretinopathy Int Ophthalmol 9 1986 37 41
4. D.R. Guyer, L.A. Yannuzzi, and J.S. Slakter et al. Digital indocyanine green videoangiography of central serous chorioretinopathy Arch Ophthalmol 112 1994 1057 1062
5. R.F. Spaide, L. Hall, and A. Haas et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy Retina 16 1996 203 213
6. T. Iida, S. Kishi, N. Hagimura, and K. Shimizu Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy Retina 19 1999 508 512
7. A. Giovannini, B. Scassellati-Sforzolini, and E. D'Altobrando et al. Choroidal findings in the course of idiopathic serous pigment epithelium detachment detected by indocyanine green videoangiography Retina 17 1997 286 293
8. C. Prünte, and J. Flammer Choroidal capillary and venous congestion in central serous chorioretinopathy Am J Ophthalmol 121 1996 26 34
9. W.M. Chan, D.S. Lam, and T.Y. Lai et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level Br J Ophthalmol 87 2003 1453 1458
10. F. Cardillo Piccolino, C.M. Eandi, and L. Ventre et al. Photodynamic therapy for chronic central serous chorioretinopathy Retina 23 2003 752 763
11. M. Taban, D.S. Boyer, E.L. Thomas, and M. Taban Chronic central serous chorioretinopathy: photodynamic therapy Am J Ophthalmol 137 2004 1073 1080
12. U. Schlotzer-Schrehardt, A. Viestenz, and G.O. Naumann et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes Graefes Arch Clin Exp Ophthalmol 240 2002 748 757
13. T.Y. Lai, W.M. Chan, and D.S. Lam Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy Am J Ophthalmol 137 2004 826 833
14. R. Tzekov, T. Lin, and K.M. Zhang et al. Ocular changes after photodynamic therapy Invest Ophthalmol Vis Sci 47 2006 377 385
15. W.M. Chan, T.Y. Lai, and R.Y. Lai et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial Ophthalmology 115 2008 1756 1765
16. T.Y. Lai, W.M. Chan, and H. Li et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study Br J Ophthalmol 90 2006 869 874
17. J.L. Kim, H.W. Kim, and I.H. Yoon Photodynamic therapy with verteporfin for short time for chronic central serous chorioretinopathy [in Korean] J Korean Ophthalmol Soc 49 2008 1078 1086
18. M. Reibaldi, F. Boscia, and T. Avitabile et al. Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy Eur J Ophthalmol 19 2009 154 158
19. M. Reibaldi, N. Cardascia, and A. Longo et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial Am J Ophthalmol 149 2010 307 315
20. J.Y. Shin, S.J. Woo, H.G. Yu, and K.H. Park Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy Retina 31 2011 119 126
21. K.B. Schaal, A.E. Hoeh, and A. Scheuerle et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy Eur J Ophthalmol 19 2009 613 617
22. M. Inoue, K. Kadonosono, and Y. Watanabe et al. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy Ophthalmologica 225 2011 37 40
23. J.Y. Lee, J.B. Chae, and S.J. Yang et al. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy [letter][report online] Acta Ophthalmol 89 2011 e293 e294
24. M.J. Koss, I. Beger, and F.H. Koch Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy Eye (Lond) 26 2012 307 314
25. O. Artunay, E. Yuzbasioglu, and R. Rasier et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study Curr Eye Res 35 2010 91 98
26. F. Semeraro, M.R. Romano, and P. Danzi et al. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy Jpn J Ophthalmol 56 2012 608 612
27. S.H. Bae, J.W. Heo, and C. Kim et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy Am J Ophthalmol 152 2011 784 792
28. J.W. Lim, M.U. Kim, and M.C. Shin Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy Retina 30 2010 1465 1471
29. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
30. D.M. Brown, P.K. Kaiser, and M. Michels et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444